Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
| Autor: | A. Saha, Teresa A. Pigott, William H. Carson, Gary G. Ingenito, Siegfried Kasper, Robert D. McQuade, Mirza Ali, Donald G. Archibald, Ronald N. Marcus, Mark N. Lerman |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Aripiprazole Atypical antipsychotic Quinolones Partial agonist Piperazines Double-Blind Method Extrapyramidal symptoms Recurrence Internal medicine medicine Haloperidol Humans Pharmacology (medical) Neurologic Examination Psychiatric Status Rating Scales Pharmacology Positive and Negative Syndrome Scale business.industry Long-Term Care Discontinuation Psychiatry and Mental health Treatment Outcome Tolerability Anesthesia Acute Disease Schizophrenia Female Schizophrenic Psychology medicine.symptom business Antipsychotic Agents medicine.drug |
| Zdroj: | The International Journal of Neuropsychopharmacology. 6:325-337 |
| ISSN: | 1469-5111 1461-1457 |
| DOI: | 10.1017/s1461145703003651 |
| Popis: | Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. Aripiprazole demonstrated long-term efficacy that was comparable or superior to haloperidol across all symptoms measures, including significantly greater improvements for PANSS negative subscale scores and MADRS total score (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|